Veritas-Cannevert Commences Preparation of First Clinical Trials of Cannabis Targeting Pain
(firmenpresse) - Veritas-Cannevert Commences Preparation of First Clinical Trials of Cannabis Targeting Pain
January 31st, 2017, Vancouver, B.C. - Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that it is working with its research arm, Cannevert Therapeutics Ltd. to design and implement the first clinical trials of cannabis strains targeting pain. Leading contract research organizations (CROs) with clinical experience of evaluating cannabis and pain are being considered for cost estimates and timelines.
Veritas CEO, Dr. Lui Franciosi indicated that, Canneverts chemical and animal studies have identified suitable strains that warrant immediate human trials, which will be done to the highest standards at institutes of high repute.
Veritas and Cannevert intend to implement these clinical trials this year that meets the highest quality standards, i.e., Good Clinical Practices (GCPs). CROs with experience in evaluating cannabis for the treatment of pain are currently being visited and screened for suitability. Once a site is identified and a contract negotiated, a formal announcement will be made.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTLs unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The companys commercial mission is to patent protect CTLs IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. Although Veritas has advanced $1,250,000 to CTL, no ownership interest will be earned by Veritas until the entire $1.5 million is received. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir(at)veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
Leseranfragen:
" alt="Power Metals Corp Creates Lithium Oilfield Brine Advisory Board; Appoints Former Gulf Oil Executive
Datum: 01.02.2017 - 11:34 Uhr
Sprache: Deutsch
News-ID 521200
Anzahl Zeichen: 3992
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 315 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Veritas-Cannevert Commences Preparation of First Clinical Trials of Cannabis Targeting Pain
"
steht unter der journalistisch-redaktionellen Verantwortung von
Veritas Pharma Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
